Product menu

Pictures of patients

Nearly everyone ≥50 years old is at risk for shingles and should be protected against shingles — even Jennifer, Sanjay, John, and Karl1,2

PREV
NEXT
Image of Jennifer

Meet Jennifer

“I live at full speed. But no matter what’s going on at home or how much work there is at the shop, I always try to prepare a healthy dinner and eat with my family. As the ‘chauffeur,’ I also drive the kids to school and their activities. My life is busy, but I wouldn’t trade it for anything.”

She feels healthy, but she’s still at risk.

Who are the people in Jennifer’s life?

  • Her husband and two children in high school
  • The employees in her flower shop
  • Her running buddies

Lifestyle:

She eats healthy, walks every day, and runs a few times a week

Medical history:

No current medical issues, varicella infection during childhood

Interaction with HCP:

Diligent about annual physicals and is proactive in discussing lifestyle changes to help keep herself healthy

Recommendation opportunity:

During preventative health screening or routine check-up

Recommend SHINGRIX because:

She is at risk for developing shingles and eligible for vaccination1,3

HCP = healthcare professional.

Not actual patients or quotes.

Patient Survey Results

Based on Canadian market research conducted by IPSOS in 2019:

64 percent Icon

of respondents* ranked their healthcare provider’s recommendation among the main drivers when deciding to vaccinate.4

* The sample reflects a representative sampling of n=800 Canadians aged 50–70 years who are aware of the condition of shingles and agreed to participate in the online survey.

20 percent Icon

of respondents† said they didn’t receive a HZ vaccine, as they assumed their healthcare provider would bring it up if they needed it. An additional 19% of these same patients stated they did not receive a HZ vaccine, as their healthcare provider didn’t recommend the vaccine.4

† The sample reflects a representative sampling of n=546 Canadians aged 50–70 years who are aware of the condition of shingles, have not yet been vaccinated and do not have immediate plans to do so, and that agreed to participate in the online survey.

Graph icon

Efficacy data for SHINGRIX

Vaccine efficacy profile was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70).3

Learn more
Virus icon

Did you know age is the dominant driver of shingles?

Learn about age-related decline in immunity.5

Learn more
Vaccine icon

Dosing and administration

Discover more about administering the vaccine and discussing shingles and vaccination with your patients.

Learn more

References:

  1. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.
  2. Public Health Agency of Canada. Canada Communicable Disease Report. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on the Recommended Use of Herpes Zoster Vaccine. January 2010. Available at: https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/publicat/ccdr-rmtc/10pdf/36-acs-1.pdf. Accessed November 17, 2023.
  3. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  4. Data on file: IPSOS Market Research, 2019. GlaxoSmithKline Inc.
  5. Harpaz R, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1–30.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24

Open cookie banner
Hide cookie banner